Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.49 |
| ▸ | HSD17B14 | Q9BPX1 | 8/20 | 0.48 |
| ▸ | IGFBP5 | P24593 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.39 |
| ▸ | IGFBP3 | P17936 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29411763 | 1.00 | MGAM (0.49) | MGAMHSD17B14IGFBP5KDM4EKMT2A | |
| SCHEMBL20772073 | 0.87 | MGAM (0.53) | MGAMHSD17B14IGFBP5KDM4EKMT2A | |
| SCHEMBL9319235 | 0.85 | MGAM (0.55) | MGAMHSD17B14IGFBP5KDM4EKMT2A | |
| SCHEMBL12405037 | 0.81 | MGAM (0.63) | MGAMKDM4EKMT2ATDP1ALOX15 | |
| SCHEMBL9220609 | 0.79 | MGAM (0.61) | MGAMKDM4EKMT2ATDP1ALOX15 | |
| SCHEMBL18191203 | 0.78 | MGAM (0.47) | MGAMHSD17B14IGFBP5KDM4EKMT2A | |
| SCHEMBL22346868 | 0.78 | MGAM (0.47) | MGAMHSD17B14IGFBP5KDM4EKMT2A | |
| SCHEMBL7170725 | 0.77 | MGAM (0.58) | MGAMHSD17B14KDM4EKMT2ATDP1 | |
| SCHEMBL5180091 | 0.75 | MGAM (0.56) | MGAMHSD17B14KDM4EKMT2ATDP1 | |
| SCHEMBL950437 | 0.74 | MGAM (0.60) | MGAMHSD17B14KDM4EKMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339871-A1 | COMPOUNDS AND METHODS OF MODULATING 17B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 | METREA BIOSCIENCES INC (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339871-A1 | COMPOUNDS AND METHODS OF MODULATING 17B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 | METREA BIOSCIENCES INC (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339871-A1 | COMPOUNDS AND METHODS OF MODULATING 17B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 | METREA BIOSCIENCES INC (US) | 2023-10-26 | — | — | US | disclosed |
| EP-4200286-A1 | COMPOUNDS AND METHODS OF MODULATING 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 | Metrea Biosciences, Inc. (US) | 2023-06-28 | — | — | EP | disclosed |
| CN-115916762-A | Compounds and methods for modulating 17 beta-hydroxysteroid dehydrogenase type 13 | 梅特雷亚生物科学股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| WO-2022040324-A1 | COMPOUNDS AND METHODS OF MODULATING 17β-ΗYDROXYSTEROID DEHYDROGENASE TYPE 13 | METREA BIOSCIENCES, INC. (US) | 2022-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339871-A1 | COMPOUNDS AND METHODS OF MODULATING 17B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 | HSD17B1, HSD17B13, HSD17B11 | MGAM 1543/4885HSD17B14 12/4885IGFBP5 2689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.